Reduction in PINP, a marker of bone metabolism, with raloxifene treatment and its relationship with vertebral fracture risk
Authors:
- J.-Y ReginsterJRJ.-Y Reginster
- S SarkarSSS Sarkar
- B ZegelsBZB Zegels
- Y HenrotinYHY Henrotin
- O BruyereO Bruyere
- D AgnusdeiDAD Agnusdei
- J ColletteJCJ Collette
Abstract
No abstract availableKeywords
This publication has 31 references indexed in Scilit:
- Efficacy of Raloxifene on Vertebral Fracture Risk Reduction in Postmenopausal Women with Osteoporosis: Four-Year Results from a Randomized Clinical TrialThe Journal of Clinical Endocrinology & Metabolism, 2002
- Biochemical Indices of Bone Turnover and the Assessment of Fracture ProbabilityOsteoporosis International, 2002
- Treatment of postmenopausal osteoporosisThe Lancet, 2002
- Early Effects of Raloxifene on Clinical Vertebral Fractures at 12 Months in Postmenopausal Women With OsteoporosisArchives of internal medicine (1960), 2002
- Improvement in spine bone density and reduction in risk of vertebral fractures during treatment with antiresorptive drugsThe American Journal of Medicine, 2002
- Raloxifene and Cardiovascular Events in Osteoporotic Postmenopausal WomenJAMA, 2002
- Relationships Between Bone Mineral Density and Incident Vertebral Fracture Risk with Raloxifene TherapyJournal of Bone and Mineral Research, 2002
- A method to assess the proportion of treatment effect explained by a surrogate endpointStatistics in Medicine, 2001
- Continued Breast Cancer Risk Reduction in Postmenopausal Women Treated with Raloxifene: 4-Year Results from the MORE TrialBreast Cancer Research and Treatment, 2001
- Reduction of Vertebral Fracture Risk in Postmenopausal Women With Osteoporosis Treated With RaloxifeneResults From a 3-Year Randomized Clinical TrialJAMA, 1999